Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).
Eleven patients with prostatic cancer maintained on monthly depot Zoladex (ICI 118,630) from 20 to 23.5 months are described. All are in clinical remission. Castrate levels of testosterone are maintained, and low levels of LH and FSH were observed. Contrary to a prior report, persistent blockage of the pituitary-gonadal axis is achieved and maintained with no detectable adverse side effects.
D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D005640:Follicle Stimulating Hormone / Q000097:blood; D017273:Goserelin; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D010902:Pituitary Gland / Q000187:drug effects*; D011471:Prostatic Neoplasms / Q000628:therapy*; D013737:Testis / Q000187:drug effects*; D013739:Testosterone / Q000097:blood; D013997:Time Factors
D003692:Delayed-Action Preparations; D017273:Goserelin; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin